1型、2型和3型炎症血液标志物与急性失代偿期肝硬化严重程度相关
该前瞻性研究纳入394例急性失代偿期肝硬化(ADC)患者,按严重程度分为无器官功能障碍、单纯器官功能障碍、无ACLF的器官衰竭和ACLF四组,分析入组时血液炎症标志物与ADC恶化的关联。校正包括诱因在内的混杂因素后,中性粒细胞计数升高、IL-25、IL-6、IL-22、sCD163升高、淋巴细胞计数降低及IFN-γ降低均与进展至更严重阶段的更高风险独立相关。
要点
- 中性粒细胞计数升高与ADC进展风险增加独立相关(校正cOR 1.17,95%CI 1.06-1.28)。
- 2型细胞因子IL-25升高与进展风险增加相关(校正cOR 1.21,95%CI 1.06-1.39)。
- 3型细胞因子IL-6和IL-22升高与进展风险增加相关(校正cOR分别为1.15和1.16)。
核心结论
- 在ADC患者中,1型、2型和3型炎症相关细胞因子血液水平改变、中性粒细胞增多、淋巴细胞减少和抗炎信号升高,分别与进展至ACLF风险增加相关,且独立于临床明显诱因的存在。
研究设计与样本
- 前瞻性纳入394例因ADC入院的患者,按严重程度分为无器官功能障碍(n=168)、单纯器官功能障碍(n=72)、无ACLF的器官衰竭(n=91)和ACLF(n=63)四组。
- 入组时获取临床血细胞计数和血清炎症标志物水平(包括与1型、2型和3型炎症相关的可溶性标志物)。
- 采用相邻类别logit模型的序数回归分析,校正包括诱因在内的混杂因素,评估各血液炎症标志物变化与ADC恶化的关联。
主要发现
- 中性粒细胞计数升高与进展至下一更严重阶段风险增加相关(校正cOR 1.17,95%CI 1.06-1.28)。
- 2型细胞因子IL-25升高(校正cOR 1.21,95%CI 1.06-1.39)、3型细胞因子IL-6升高(校正cOR 1.15,95%CI 1.02-1.28)和IL-22升高(校正cOR 1.16,95%CI 1.03-1.30)与进展风险增加相关。
- 抗炎可溶性CD163升高与进展风险增加相关(校正cOR 1.94,95%CI 1.58-2.38)。
- 淋巴细胞计数降低(校正cOR 0.77,95%CI 0.68-0.87)和1型细胞因子IFN-γ水平降低(校正cOR 0.85,95%CI 0.75-0.95)与进展风险增加相关。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: In patients with acutely decompensated cirrhosis (ADC) who present with clinically apparent precipitants (i.e., infections, acute liver injury), alterations in blood markers of inflammation associate with progression toward severe phenotypes (e.g., acute-on-chronic liver failure [ACLF]). However, it is unclear whether alterations in blood inflammatory markers associate with progression of ADC independently of precipitants. METHODS: We prospectively enrolled 394 patients admitted for ADC who were classified into four phenotypes of increasing severity: no organ dysfunction (n = 168), organ dysfunction alone (n = 72), organ failure without ACLF (n = 91), and ACLF (n = 63). Clinical blood cell counts and serum levels of inflammatory markers (including soluble markers related to type-1, type-2, and type-3 inflammation) were obtained at enrollment. Ordinal regression with adjacent categories logit model adjusted for confounders (including precipitants) was used to analyze associations between changes in each blood inflammatory marker and the worsening of ADC. RESULTS: Inflammatory markers that were associated with a higher risk of progressing to the next more severe stage were as follows: increasing neutrophil counts (adjusted common odds ratio [cOR] 1.17, 95% CI 1.06-1.28); increasing levels of the type-2 cytokine interleukin (IL)-25 (cOR 1.21, 95% CI 1.06-1.39), type-3 cytokines IL-6 (cOR 1.15, 95% CI 1.02-1.28) and IL-22 (cOR 1.16, 95% CI 1.03-1.30), or anti-inflammatory soluble CD163 (cOR 1.94, 95% CI 1.58-2.38); decreasing lymphocyte counts (cOR 0.77, 95% CI 0.68-0.87); or decreasing levels of the type-1 cytokine IFN-γ (cOR 0.85, 95% CI 0.75-0.95). CONCLUSIONS: Among patients with ADC, alterations in blood levels of cytokines related to type-1, type-2 and type-3 inflammation, together with neutrophilia, lymphopenia and elevated anti-inflammatory signals were individually associated with an increased risk of progressing toward ACLF, independently of the presence of clinically apparent precipitants. IMPACT AND IMPLICATIONS: This study reveals that among patients with acutely decompensated cirrhosis, alterations in blood levels of cytokines related to type-1, type-2 and type-3 inflammation, together with neutrophilia, lymphopenia and elevated anti-inflammatory signals were individually associated with increased risk of progressing toward acute-on-chronic liver failure, independently of the presence of clinically apparent precipitants. These findings raise questions about the role of impaired barrier tissues and dysregulated production of blood immune cells in the pathophysiology of severe phenotypes of acutely decompensated cirrhosis, stimulating research to identify potential new biomarkers and targets for novel therapeutic approaches.
引用
- Cao Z, Yao Y, Cai M, et al. Blood markers for type-1, -2, and -3 inflammation are associated with severity of acutely decompensated cirrhosis. J Hepatol. 2024. PMID: 39490592. doi:10.1016/j.jhep.2024.10.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。